Skip to main content
SpringerLink
Log in

Prescribing pattern of antidiabetic drugs and achievement of glycemic control in T2DM patients tertiary care hospital in North India

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

An Erratum to this article was published on 08 December 2013

Abstract

Study was undertaken to identify patterns of antidiabetic drugs prescribing in established type 2 diabetes mellitus. Patients with established T2DM who attended the endocrinology Outpatient Clinic in Postgraduate Institute of Medical Education and Research, Chandigarh, India were evaluated for social, demographical and clinical variables and medications. 1185 established T2DM patients were assessed. Metformin was the most commonly prescribed drug [827 (70 %)], followed by insulin [627 (53 %)], sulfonylureas [520 (44 %)], and pioglitazone [329 (28 %)]. The most frequently prescribed monotherapy was insulin [214 (62 %)], followed by metformin in 81 (23 %), sulfonylurea in 49 (14 %) and pioglitazone in 4 (1 %) patients. 704 (59 %) treated patients had uncontrolled hyperglycemia. Family history (OR 1.76, 95%CI 1.18, 2.64), diabetes duration (OR 2.62, 95 % CI 2.05, 3.36), HbA1c (OR 1.25, 95%CI 1.01, 1.50), neuropathy(OR 1.57, 95 % CI, 1.14, 2.2), nephropathy(OR 1.77, 95 % CI 1.40, 2.24), retinopathy (OR 1.97, 95 % CI 1.63, 2.40), coronary arterial disease (CAD) (OR 1.57, 95 % CI, 1.14, 2.2) and diabetic foot (OR 1.62, 95 % CI 1.12, 2.40) were all significantly associated with insulin therapy. Obese and overweight patients were prescribed oral antidiabetic drugs. Medication use was consistent with practice guidelines in T2DM, even though the outcome did not reach the goal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–9.

    Article  PubMed  Google Scholar 

  2. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–52.

    Article  PubMed  CAS  Google Scholar 

  3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.

    Article  PubMed  CAS  Google Scholar 

  4. Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55). Diabetes Care. 2001;24:1167–74.

    Article  PubMed  CAS  Google Scholar 

  5. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.

    Article  PubMed  CAS  Google Scholar 

  6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.

    Article  PubMed  CAS  Google Scholar 

  7. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

    Article  PubMed  CAS  Google Scholar 

  8. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.

    Article  PubMed  CAS  Google Scholar 

  9. Cobitz AR, Ambery P. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Response to Nathan et al. Diabetes Care. 2009;32:e58.

    Article  PubMed  Google Scholar 

  10. Sibal L, Home PD. Management of type 2 diabetes: NICE guidelines. Clin Med. 2009;9:353–7.

    Article  PubMed  Google Scholar 

  11. Indian diabetes guidelines. J Assoc Physicians India. 2002;50:295.

    Google Scholar 

  12. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317:465–8.

    Article  PubMed  CAS  Google Scholar 

  13. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003;362:1225–30.

    Article  PubMed  Google Scholar 

  14. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969;22:158–61.

    Article  PubMed  CAS  Google Scholar 

  15. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470–5.

    PubMed  CAS  Google Scholar 

  16. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077–80.

    PubMed  CAS  Google Scholar 

  17. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:786–806.

  18. Hippisley-Cox J, Pringle M. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet. 2004;364:423–8.

    Article  PubMed  CAS  Google Scholar 

  19. Secnik K, Yurgin N, Lage MJ, McDonald-Everett C. Patient characteristics, glycemic control, and the use of antidiabetic agents among individuals diagnosed with type 2 diabetes: Evidence from the UK. . ISPOR European Meeting; 2005 October 2005.

  20. Yurgin N, Secnik K, Lage MJ, editor. Type 2 diabetes in Germany: Prevalence and medication use. ISPOR European Meeting, October 2005.

  21. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990–2001. Diabetes Care. 2003;26:1852–5.

    Article  PubMed  Google Scholar 

  22. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol. 2005;60:543–51.

    Article  PubMed  CAS  Google Scholar 

  23. Lusignan S, Sismanidis C, Carey IM, DeWilde S, Richards N, Cook DG. Trends in the prevalence and management of diagnosed type 2 diabetes 1994–2001 in England and Wales. BMC Fam Pract. 2005;6:13.

    Article  PubMed  Google Scholar 

  24. Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26:1847–51.

    Article  PubMed  Google Scholar 

  25. Bailey CJ. Metformin: a multitasking medication. Diab Vasc Dis Res. 2008;5:156.

    Article  PubMed  Google Scholar 

  26. Evans A, Krentz AJ. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. Drug Saf. 1999;21:7–22.

    Article  PubMed  CAS  Google Scholar 

  27. Lund SS, Vaag AA. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et al. Diabetes Care. 2009;32:e90–1.

    Article  PubMed  Google Scholar 

  28. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.

    Article  PubMed  Google Scholar 

  29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Google Scholar 

  30. Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616–25.

    Article  PubMed  CAS  Google Scholar 

  31. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244–8.

    Article  PubMed  CAS  Google Scholar 

  32. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999;130:389–96.

    Article  PubMed  CAS  Google Scholar 

  33. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 2001;30:935–82.

    Article  PubMed  CAS  Google Scholar 

  34. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28:600–6.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER)-SAS Nagar, Punjab, S.A.S. Nagar, India

    Ethiraj Dhanaraj, Rajbharm Yadav & Pramil Tiwari

  2. Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University Practice, 1 Medical Center Drive, Morgantown, WV, 26506, USA

    Amit D. Raval

  3. Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

    Anil Bhansali

Authors
  1. Ethiraj Dhanaraj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amit D. Raval
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rajbharm Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anil Bhansali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pramil Tiwari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amit D. Raval.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dhanaraj, E., Raval, A.D., Yadav, R. et al. Prescribing pattern of antidiabetic drugs and achievement of glycemic control in T2DM patients tertiary care hospital in North India. Int J Diabetes Dev Ctries 33, 140–146 (2013). https://doi.org/10.1007/s13410-013-0123-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-013-0123-5

Keywords

Search

Navigation